By Stephen Nakrosis

Genentech said Tuesday the Food and Drug Administration approved its Tecentriq plus chemotherapy to treat certain lung cancers.

The company said the approval was for the initial treatment of certain adults with metastatic non-squamous non-small cell lung cancer.

Genentech said the approval was based on results from a Phase III study that showed Tecentriq, or atezolizumab, "in combination with chemotherapy helped people live significantly longer compared to chemotherapy alone."

Genentech is a member of the Roche Group.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 03, 2019 19:06 ET (00:06 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.